Mather Group LLC. Acquires 787 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Mather Group LLC. increased its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 49.7% during the second quarter, HoldingsChannel reports. The fund owned 2,371 shares of the medical equipment provider’s stock after acquiring an additional 787 shares during the quarter. Mather Group LLC.’s holdings in Intuitive Surgical were worth $1,055,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of ISRG. Baystate Wealth Management LLC raised its position in shares of Intuitive Surgical by 150.0% during the fourth quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 45 shares during the last quarter. Creekmur Asset Management LLC raised its holdings in Intuitive Surgical by 200.0% in the 1st quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 42 shares in the last quarter. MCF Advisors LLC lifted its position in shares of Intuitive Surgical by 108.1% in the 4th quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 40 shares during the period. Able Wealth Management LLC acquired a new stake in shares of Intuitive Surgical during the 4th quarter worth approximately $28,000. Finally, Delos Wealth Advisors LLC increased its position in shares of Intuitive Surgical by 380.0% during the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 57 shares during the period. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Intuitive Surgical news, Director Amal M. Johnson sold 2,943 shares of the stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $443.30, for a total value of $1,304,631.90. Following the transaction, the director now owns 12,275 shares of the company’s stock, valued at $5,441,507.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, Director Craig H. Barratt sold 1,400 shares of Intuitive Surgical stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total transaction of $641,382.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Amal M. Johnson sold 2,943 shares of the company’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $443.30, for a total transaction of $1,304,631.90. Following the completion of the sale, the director now owns 12,275 shares of the company’s stock, valued at approximately $5,441,507.50. The disclosure for this sale can be found here. In the last 90 days, insiders sold 16,005 shares of company stock valued at $6,894,422. Company insiders own 0.90% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. Morgan Stanley raised their target price on Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a research report on Monday, July 15th. Jefferies Financial Group raised their price objective on shares of Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a report on Friday, April 19th. The Goldman Sachs Group began coverage on shares of Intuitive Surgical in a research note on Thursday, May 30th. They issued a “buy” rating and a $500.00 target price on the stock. Citigroup raised their price target on shares of Intuitive Surgical from $462.00 to $512.00 and gave the stock a “buy” rating in a research note on Wednesday, July 10th. Finally, Redburn Atlantic upgraded Intuitive Surgical from a “neutral” rating to a “buy” rating and upped their price objective for the company from $380.00 to $510.00 in a research note on Friday, August 2nd. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $442.30.

Intuitive Surgical Trading Up 2.5 %

Shares of ISRG traded up $11.35 during trading hours on Wednesday, hitting $459.01. 569,154 shares of the stock traded hands, compared to its average volume of 1,566,855. The business has a fifty day moving average of $433.72 and a 200-day moving average of $402.67. The firm has a market capitalization of $162.81 billion, a PE ratio of 80.81, a price-to-earnings-growth ratio of 4.97 and a beta of 1.39. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $468.78.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.24. The company had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The company’s revenue was up 14.5% compared to the same quarter last year. During the same period in the prior year, the company posted $1.18 EPS. As a group, equities research analysts expect that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.